Harald Moi

Harald Moi

Auto-generated profile, based on publicly available information

Harald Moi

Olafia Clinic Oslo University Hospital Institute of Medicine University of Oslo Oslo Norway

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
JJJørgen Skov Jensen
Jørgen Skov Jensen
MCM. Cusini
M. Cusini
MGM. Gomberg
M. Gomberg
HMH. Moi
H. Moi
JWJ. Wilson
J. Wilson
MUM. Unemo
M. Unemo

18 May 2015 in Sexually Transmitted Infections
Verified
Journal Article
Open access
PDF file
PHPatrick Horner
Patrick Horner
SISuzanne Ingle
Suzanne Ingle
KBKarla Blee
Karla Blee
PMPeter Muir
Peter Muir
HMHarald Moi
Harald Moi
Background Mycoplasma genitalium (MG) is an emerging important STI. Failure rates with azithromycin 1 g appear to be increasing. This may be due to the emergence of macrolide antimicrobial resistance as a consequence of extensive use of azithromycin 1 g. An extended regimen of azithromycin 500 mgs on day one then 250 mgs daily for 4 days (5 day regimen) was introduced in the 1990s for treatment of MG and has high efficacy rates (if no pre-existing macrolide resistance) and is less associated with induction of macrolide resistance. There are no comparative trials of the two regimens. Treatment of Mycoplasma genitalium Aim To undertake a meta-analysis of MG treatment studies using the two azithromycin regimens to determine which is more effective. Methods MG treatment studies were included if: patients were initially assessed for macrolide resistance genetic mutations, were treated with azithromycin 1 g or 5 days, and those who failed were again resistance genotyped. Sensitivity analyses included only patients without prior treatment. Results Five studies were identified. Compared to the 5 day regimen, azithromycin 1 g had higher failure risk (difference: 11.8%, 95% CI: 7.3%, 16.2%) and more developed macrolide resistance (risk difference: 11.8% (8.3%, 15.3%)). The 5 day regimen included 52 patients with prior doxycycline treatment. Sensitivity analysis showed a failure risk difference of 9.2% (0.9%, 17.5%). Resistance risk did not change. Conclusion Azithromycin 1 g is more likely to result in treatment failure and the development of macrolide antimicrobial resistance than 500 mgs on day one then 250 mgs daily for 4 days.

1 January 1999
Verified
Book Chapter
Closed access
PDF file
EKE. Kleist
E. Kleist
HMH. Moi
H. Moi